ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Hydroxychloroquine"

  • Abstract Number: 1743 • ACR Convergence 2021

    Whole Blood Hydroxychloroquine Levels Do Not Correlate with QTc Intervals in a Cohort of 84 SLE Patients: Evidence That Antimalarials Are Not Associated with Cardiac Conduction System Toxicity

    Mayce Haj-Ali1 and H. Michael Belmont2, 1NYU Grossman School of Medicine, New York, NY, 2NYU School of Medicine, New York, NY

    Background/Purpose: Hydroxychloroquine (HCQ) is an antimalarial drug used in the treatment of systemic lupus erythematous (SLE). There is limited data assessing cardiac toxicity as arrhythmias…
  • Abstract Number: 1753 • ACR Convergence 2021

    Hydroxychloroquine Blood Levels Are Associated with Reduced SLE Disease Activity and Improvements in Cardiovascular Risk Factors

    Laurence Magder1, Michelle Petri2 and Daniel Goldman2, 1University of Maryland, Baltimore, Baltimore, MD, 2Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: In SLE, treatment with hydroxychloroquine (HCQ) has been shown to be associated with reduced SLE flares and reduced risk of damage in several different…
  • Abstract Number: 1764 • ACR Convergence 2021

    Estimation of the Prevalence of Hydroxychloroquine-Induced Retinopathy in a Cohort of Hydroxychloroquine-Compliant Patients

    Kelley Brady, Roberta Alexander, Rory Bloch, Mark Rudolph, Karina Baggiani, Deborah Stimson and Anja Kammensheidt, Exagen Inc., Vista, CA

    Background/Purpose: HCQ is an antimalarial drug effective in the treatment of rheumatologic conditions. High blood levels, advanced age, and extended treatment duration are associated with…
  • Abstract Number: 1768 • ACR Convergence 2021

    Additional Hydroxychloroquine Therapy Regulates Adipokines in Systemic Lupus Erythematosus with Stable Disease Activity

    Risa Wakiya1, Kiyo Ueeda1, Hiromi Shimada1, Shusaku Nakashima1, Mikiya Kato1, Taichi Miyagi2, Mansour mai1, Koichi Sugihara1, Rina Semba1, Mao Mizusaki1, Tomohiro Kameda1 and Hiroaki Dobashi3, 1Kagawa University, Takamatsu, Japan, 2Kagawa University, Kidagun, Japan, 3Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: In systemic lupus erythematosus (SLE), atherosclerosis is strongly associated with vital prognosis. On the other hand, arteriosclerosis is strongly influenced by serum adipokines. The…
  • Abstract Number: 0875 • ACR Convergence 2021

    Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity

    Shivani Garg1, Karen Hansen2, Betty Chewning1 and Christie Bartels2, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
  • Abstract Number: 0989 • ACR Convergence 2021

    Risk Factors for Hydroxychloroquine Retinopathy and Its Subtypes – Prospective Adjudication Analysis of 4,899 Incident Users

    April Jorge1, Ronald Melles2, Carol Conell3, Na Lu4, Michael Marmor5, Lucy Young6, Natalie McCormick1, Yuqing Zhang7 and Hyon K. Choi8, 1Massachusetts General Hospital, Boston, MA, 2Redwood City Medical Center, Department of Ophthalmology, Kaiser Permanente Northern California, Redwood City, CA, 3Kaiser Permanente Northern California, Palo Alto, CA, 4Arthritis Research Canada, Vancouver, BC, Canada, 5Stanford University, Palo Alto, CA, 6Massachusetts Eye and Ear Institute, Harvard Medical School, Boston, MA, 7Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 8Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases; however, the known risk factors for HCQ retinopathy (its major…
  • Abstract Number: 1163 • ACR Convergence 2021

    Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence

    Shivani Garg1, Betty Chewning1, Noah Kaitz1, Shelby Gomez1 and Christie Bartels2, 1UW Madison, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is the cornerstone of SLE therapy as it improves damage-free survival in all SLE patients. Yet, in new users, as few as…
  • Abstract Number: 1462 • ACR Convergence 2021

    Hydroxychloroquine Dose and the Risk of Systemic Lupus Erythematosus Flares

    April Jorge1, Christian Mancini1, Xiaoqing Fu1, Gary Ho2, Yuqing Zhang3, Karen Costenbader4 and Hyon K. Choi5, 1Massachusetts General Hospital, Boston, MA, 2New York University, New York, NY, 3Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 4Brigham and Women's Hospital, Belmont, MA, 5Massachusetts General Hospital, Lexington, MA

    Background/Purpose: Hydroxychloroquine (HCQ) is an important treatment for systemic lupus erythematosus (SLE), known to reduce disease activity and flares. To minimize the risk of toxicity,…
  • Abstract Number: 1705 • ACR Convergence 2021

    The Impact of Age and Drug-Drug Interactions on QT Interval in Chronic Hydroxychloroquine Users

    Marco Gianpiero Antivalle1, Michele Agosti1, Giuliana La Paglia2, Alberto Batticciotto3, Maria Chiara Ditto4, SIMONE PARISI5 and Piercarlo Sarzi-Puttini6, 1L. Sacco University Hospital, Milano, Italy, 2L.Sacco University Hospital, Milano, Lombardia, Italy, 3Ospedale di Circolo - Fondazione Macchi, Varese, Lombardia, Italy, 4AOU Città della Salute e della Scienza, Torino, Italy, 5AOU Città della Salute e della Scienza, TURIN, Italy, 6L.Sacco University Hospital, Milano, Italy

    Background/Purpose: Hydroxychloroquine (HCQ) has been used safely for over 60 years in rheumatic patients. However, following its recent use in covid-19 disease, its safety has…
  • Abstract Number: 2529 • 2019 ACR/ARP Annual Meeting

    Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis

    Thibaut Naveau 1, Olivier Lichau 1, Thomas Barnetche 1, Thierry Schaeverbeke 1, Estibaliz Lazaro 2, Marie-Elise Truchetet 3 and Christophe Richez4, 1FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, 2FHU ACRONIM, Department of Internal Medecine, Centre Hospitalier Universitaire, Bordeaux, France, Pessac, France, 3FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France. Bordeaux University, CNRS 5164, 33000 Bordeaux, France, Bordeaux, France, 4Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France

    Background/Purpose: Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been used for years during pregnancy for multiple indications (malaria prevention, autoimmune disorders, etc.…). Recently, some countries face…
  • Abstract Number: 2536 • 2019 ACR/ARP Annual Meeting

    Distribution and Predictors of Whole Blood Hydroxychloroquine Levels in Clinical Rheumatology Practices in the United States

    Thierry Dervieux1, Kelley Brady 1, Don Thomas 2, John Conklin 1, Eugene Fung 3, Claudia Ibarra 1 and Michelle Petri 4, 1Exagen, Vista, CA, 2Walter Reed National Military Medical Center, Bethesda, MD, 3Arthritis & Osteoporosis Clinic, Waco, TX, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Therapeutic drug monitoring of whole blood Hydroxychloroquine (HCQ) can help identify patients at risk of flares due to underexposure (e.g. severe non-adherence, < 200…
  • Abstract Number: 2539 • 2019 ACR/ARP Annual Meeting

    Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)

    Sooyeon Kwon1, Jessica Farrell 2, Sarfaraz Hasni 3 and Shubhasree Banerjee 2, 1The Center For Rheumatology, Loudonville, NY, 2The Center for Rheumatology, LLC, Albany, NY, 3NIAMS, National Institutes of Health, Bethesda, MD

    Background/Purpose: Hydroxychloroquine (HCQ) is recommended in all patients with systemic lupus erythematosus (SLE).  Studies suggest that a significant proportion of subjects are non-adherent to daily…
  • Abstract Number: 2541 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment

    Naoto Yokogawa1, Masayuki Hashiguchi 2, Yoshiki Nagai 3, Kota Shimada 4, Shoji Sugii 1, Miho Oshima 5, Keigo Setoguchi 6 and Mikiko Shimizu 7, 1Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, 2Division for Evaluation and Analysis of Drug Information, Faculty of Pharmacy, Keio University, Tokyo, Japan, 3Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan, 4Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, 5Division of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan, 6Tokyo Metropolitan Cancer and Infectious Dease Center Komagome Hospital, Tokyo, Tokyo, Japan, 7Department of Drug Metabolism and Pharmacokinetics, Faculty of Pharmaceutical Sciences, Aomori University, Aomori, Japan

    Background/Purpose: A low glomerular filtration rate (GFR: < 60 mL/min/1.73 m2) is an established risk of hydroxychloroquine (HCQ) retinopathy and is presumably related to higher…
  • Abstract Number: 2560 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

    Maria Salgado Guerrero1, Alejandra Londono Jimenez 2, Chrisanna Dobrowolsky 2, Shudan Wang 2, Wenzhu B. Mowrey 3 and Anna Broder 2, 1Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Hydroxychloroquine (HCQ) use in SLE has been associated with a lower risk of end-organ damage, SLE flares, and thrombosis1,2. However the benefits of HCQ…
  • Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting

    Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

    Tatiana Pedrosa 1, Sandra G. Pasoto 1, Emily Yuki2, Nadia Aikawa 1, Eduardo Borba 1, Julio Ferreira Filho 1, Pedro Carricondo 3, Caio Zanetti 1, Paola Conde 1, Nicole Fontoura 1, Paschoalina Romano 4, Valdemir Carvalho 5, Clovis Silva 6 and Eloisa Bonfa 7, 1Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, 3Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 4Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 5Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, 6Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
  • 1
  • 2
  • 3
  • …
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology